Jerini

Jerini AG was a German pharmaceutical and biotechnology company headquartered in Berlin. Founded in 1994, it concentrated on discovering and developing medicines based on peptides and related molecular structures, with a particular emphasis on diseases for which existing therapies were limited or inadequate. The company’s core scientific platform, known as Peptides-to-Drugs (P2D), was designed to convert peptide leads into drug candidates that could be developed as injectable peptidomimetics or, where feasible, as orally available small molecules. Jerini’s business model combined internally generated research programs with compounds obtained through licensing and collaborations. It intended to commercialize medicines independently in specialized or niche indications while using larger pharmaceutical partners for products requiring broader international development, regulatory, manufacturing, or commercial infrastructure. Its research interests extended across inflammatory disease, ophthalmology, and oncology. One of its most advanced internal programs targeted age-related macular degeneration, including the preclinical compound JSM 6427, although this program did not become the company’s principal commercial product. The company’s defining commercial asset was icatibant, marketed as Firazyr. Jerini licensed the compound from Aventis in 2001. Icatibant is a bradykinin B2-receptor antagonist intended to block the effects of bradykinin, a mediator involved in the swelling attacks associated with hereditary angioedema. Firazyr received approval for hereditary angioedema in the European Union in July 2008 and subsequently obtained approval from the United States Food and Drug Administration on August 25, 2011. These approvals made the program the central example of Jerini’s strategy of advancing a targeted medicine for a rare condition. Jerini was financed by venture-capital investors including TVM and HealthCap. It later entered the Prime Standard of the Frankfurt Stock Exchange under the ticker JI4. The company was acquired by Shire plc in 2008, bringing Jerini’s principal pharmaceutical assets and development capabilities into Shire’s specialty-pharmaceutical organization. Following the acquisition, Jerini no longer operated as an independent pharmaceutical company. Its subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH were subsequently acquired by Theracode GmbH of Mainz in 2009. JPT had supplied peptides and peptide microarrays, giving the transaction a separate technology-services and research-tools dimension. Jerini’s legacy rests chiefly on the development and commercialization pathway of icatibant and on its attempt to build a repeatable platform for turning biologically active peptides into practical drug candidates. The company is now defunct as an independent corporate entity, but its principal product and technology programs continued through successor owners and partners.

Jerini began operations in Berlin in 1994 as a pharmaceutical company built around peptide science. Its research proposition was that peptides could provide highly selective starting points for medicines, but that their clinical usefulness could be improved by converting them into more durable or administrable structures. The company organized this approach under its Peptides-to-Drugs platform, or P2D. The P2D platform was intended to identify peptide lead structures and then systematically transform them into peptidomimetics or small molecules. Injectable peptidomimetics could be suitable for acute treatment, while orally available compounds could potentially support chronic treatment. This platform approach shaped Jerini’s internal research portfolio and was applied to programs in ophthalmology, oncology, and inflammatory disease. Its ophthalmology work included JSM 6427, a preclinical candidate investigated for age-related macular degeneration. Jerini also pursued external assets and partnerships rather than relying exclusively on internal discovery. In 2001 it licensed icatibant from Aventis. The compound inhibits signaling through the bradykinin B2 receptor, a mechanism relevant to hereditary angioedema attacks. Icatibant became Jerini’s lead development and commercial program and was given the brand name Firazyr. The company used a specialist-commercialization model. Jerini aimed to market medicines itself when the indication was sufficiently focused, while seeking partners for products requiring larger-scale development or sales operations. Its financing included venture-capital backing from TVM and HealthCap. Jerini also became a publicly traded company on the Prime Standard of the Frankfurt Stock Exchange under the symbol JI4. Firazyr achieved a major European regulatory milestone in July 2008, when it was approved for hereditary angioedema in all European Union member states. In the same year, Shire plc acquired Jerini. The transaction transferred Jerini’s principal pharmaceutical operations and assets to Shire and marked the end of Jerini as an independent listed company. Firazyr subsequently received United States FDA approval on August 25, 2011. The post-acquisition corporate history also involved Jerini’s technology subsidiaries. In 2009, Theracode GmbH of Mainz acquired Jerini US Inc. and JPT Peptide Technologies GmbH. JPT provided peptides and peptide microarrays, representing a research-tools and services activity distinct from the branded pharmaceutical development business. Jerini’s independent corporate life therefore spanned the development of a peptide-focused discovery platform, the licensing and advancement of icatibant, public-market financing, regulatory approval in Europe, and acquisition by Shire. Although the company itself is defunct, its most important product and elements of its technology portfolio continued under successor ownership.

• 2011

  Firazyr gains United States FDA approval

  [1]Jerinien.wikipedia.org

  The FDA approved Firazyr for hereditary angioedema on August 25, 2011.

• 2009

  Theracode acquires Jerini subsidiaries

  [1]Jerinien.wikipedia.org

  Theracode GmbH acquired Jerini US Inc. and JPT Peptide Technologies GmbH, a provider of peptides and peptide microarrays.

• 2008

  Firazyr gains European Union approval

  [1]Jerinien.wikipedia.org

  Firazyr was approved in all European Union member states for hereditary angioedema in July 2008.

• 2008

  Shire acquires Jerini

  [1]Jerinien.wikipedia.org

  Shire plc acquired Jerini, bringing the company’s pharmaceutical assets and development programs into Shire and ending Jerini’s independent corporate existence.

• 2001

  Icatibant is licensed from Aventis

  [1]Jerinien.wikipedia.org

  Jerini in-licensed icatibant from Aventis, establishing the compound that would later be commercialized as Firazyr as its lead program.

• 1994

  Jerini begins operations

  [1]Jerinien.wikipedia.org

  Jerini began operating as a Berlin-based pharmaceutical company focused on peptide-based drug discovery and development.

A specialist pharmaceutical and biotechnology company focused on translating peptide biology into targeted medicines, particularly for rare diseases and therapeutic areas with limited treatment options.

• Rare-disease pharmaceutical · 2008

  Firazyr (icatibant)

  Firazyr is the brand name associated with icatibant, a bradykinin B2-receptor antagonist. Jerini licensed icatibant from Aventis in 2001 and developed it for hereditary angioedema, a rare disorder characterized by potentially severe swelling attacks. The product received European Union approval in July 2008 and United States FDA approval on August 25, 2011. It became Jerini’s principal commercial and strategic asset and continued under successor ownership after Shire acquired the company.

• Ophthalmology drug candidate

  JSM 6427

  JSM 6427 was an internally developed Jerini compound investigated in the ophthalmology field, particularly for age-related macular degeneration. The program was based on Jerini’s peptide-derived drug-discovery approach and showed efficacy in preclinical models according to the referenced company description. It remained a development-stage candidate rather than a documented commercial product.

• Drug-discovery platform

  Peptides-to-Drugs (P2D)

  P2D was Jerini’s proprietary technology platform for identifying peptide drug leads and converting them into more drug-like structures. Depending on the therapeutic objective, the platform could support peptidomimetic candidates intended for injection or small-molecule candidates with potential for oral administration. Jerini applied the platform to programs in inflammation, oncology, and ophthalmology.

• Research tools and services

  Peptides and peptide microarrays

  Through JPT Peptide Technologies GmbH, part of the Jerini group before its later acquisition by Theracode, the business supplied peptides and peptide microarrays. These products supported laboratory research and complemented Jerini’s therapeutic drug-discovery activities.

• 2008

  Accept acquisition by ShireM&A

  Background

  Jerini had advanced Firazyr toward commercialization and operated as a specialist pharmaceutical company with a peptide-focused technology platform.

  Action taken

  Shire plc acquired Jerini and integrated its pharmaceutical assets and capabilities.

  Aftermath

  Jerini ceased to operate as an independent company, while Firazyr continued through Shire and later successor ownership.

  Source

• 2001

  License icatibant from AventisStrategy

  Background

  Jerini sought to build a pharmaceutical portfolio combining its own peptide-discovery programs with externally sourced development assets.

  Action taken

  The company in-licensed icatibant from Aventis and made the compound the central focus of its lead development program.

  Aftermath

  Icatibant was developed as Firazyr and later received regulatory approvals for hereditary angioedema in the European Union and United States.

  Source

1. 1Jerinien.wikipedia.org